Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...

Prof. Nicolas Barry-Delongchamps, Professor of Urology at Cochin Hospital and Principal Investigator of the VIOLETTE trial, will present the final results and one-year patients follow-up from the ...

Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new recommendations from international experts.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.